医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Blaze Bioscience Announces Poster Presentation at ASCO 2015 Annual Meeting

2015年05月27日 PM07:00
このエントリーをはてなブックマークに追加


 

SEATTLE & MELBOURNE, Australia

Blaze Bioscience, the Tumor Paint Company®, a biotechnology company focused on guided cancer therapy, and its subsidiary, Blaze Bioscience Australia Pty Ltd, announced today that the company’s Senior Vice President of Development, Dennis Miller, Ph.D., will present at the American Society of Surgical Oncology (ASCO) 2015 Annual Meeting, taking place in Chicago, IL on May 29-June 2, 2015.

The poster presentation, titled “Phase 1 dose escalation and expansion safety study of BLZ-100 in subjects with skin cancer,” will highlight the company’s first-in-human study.

Details of the poster presentation are as follows:

Trials in Progress Presentation
Date: Monday, June 1, 2015
Time: 1:15 PM – 4:45 PM CDT
Location: S Hall A
Poster Number: 324b
Abstract Number: TPS9084

About Tumor Paint BLZ-100

BLZ-100 is the first product candidate from Blaze’s Tumor Paint platform and consists of an Optide (optimized peptide), which binds and internalizes into cancer cells, and a fluorescent dye, which emits light in the near-infrared range. Tumor Paint products are designed to provide real-time, high-resolution intraoperative visualization of cancer cells, enabling more precise, complete resection of cancer throughout surgery. Preclinical utility of Tumor Paint technology has been demonstrated in a wide range of cancer types, including brain, lung, breast, prostate, colorectal, and sarcomas. BLZ-100 is currently in Phase 1 proof-of-concept clinical studies to evaluate safety and imaging characteristics of BLZ-100 in solid tumor cancers.

About Blaze Bioscience

Blaze Bioscience, Inc. is a privately held biotechnology company focused on guided cancer therapy. Blaze was founded in 2010 by Dr. Jim Olson, a pediatric neuro-oncologist at the Fred Hutchinson Cancer Research Center and Seattle Children’s Hospital, and Heather Franklin, a former senior business executive from ZymoGenetics, and is working to develop Tumor Paint™ products and Optide-based guided cancer therapeutics. Surgery is first-line therapy for most solid tumor cancers and Tumor Paint products intend to improve cancer surgery by providing real-time, high-resolution visualization of cancer cells throughout surgery. The ability to see cancer cells in real time and high resolution throughout surgery should enable better detection and more complete and precise surgical removal of cancer—while sparing surrounding normal tissue. In addition to the Tumor Paint platform, Blaze is collaborating with the Fred Hutchinson Cancer Research Center to discover and develop guided cancer therapeutics as part of the Optides platform. This program extends the expertise gained in developing the Tumor Paint platform to optimized knottin peptide conjugates for therapeutic and imaging applications. For additional information, please visit www.blazebioscience.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150527005318/en/

CONTACT

Media:
Blaze Bioscience, Inc.
Lauren Nelson, 206-535-8144
lauren.nelson@blazebioscience.com
or
Investor
Relations:
SOS Communications LLC
Susan Specht Oram,
360-535-3035
spechtoram@gmail.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at the American Society of Clinical Oncology (ASCO) and the Congress of the European Hematology Association (EHA) Annual Meetings
  • Cerveau Technologies, Inc.与日本东京都老人综合研究所签订研究协议
  • 继美国和英国之后,中国向Personalis, Inc.签发ACE©技术专利,扩大了其在国际上的知名度
  • セルヴォー・テクノロジーズが日本の東京都健康長寿医療センター研究所と研究契約を締結
  • 国際的な食品・飲料企業の連合が、世界の供給食料から人工トランス脂肪酸を排除するための世界保健機関とResolve to Save Livesによる呼び掛けを支持